COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Phase 1/1b Study To Evaluate The Safety And Activity Of TTX-030 (Anti-CD39) In Combination With Budigalimab And/Or Chemotherapy In Subjects With Advanced Solid Tumors

Protocol No
TRISHULA-TTX-030-002
Principal Investigator
Ben George
Phase
I
Summary
TTX-030 is protein that is a monoclonal antibody that affects a pathway on the surface of cells called the adenosine pathway, by inhibiting a protein called CD39. Cancer cells use the adenosine pathway to control the body’s immune system response and help cancer cells grow. By stopping CD39, TTX-030 changes the pathway and may help your immune system fight cancer cells. Budigalimab is a protein called a monoclonal antibody targeting PD-1; it aims to improve the immune response against cancer rather than targeting the tumor directly, allowing the body itself to fight the tumor. The FDA has approved the regimen of mFOLFOX6 or a chemotherapy agent docetaxel to treat various tumor types, including prostate, colon and stomach cancers. However, combination of TTX-030 and budigalimab, and/or mFOLFOX6 or docetaxel is an investigational use of the drugs.
Description
This study is being done for the following purposes:
To test the safety of TTX-030 combination therapy in various cancer types
To see if TTX-030 combination therapy works against various cancer types
To see how much TTX-030 combination therapy is in the blood at specific times after dosing and how the body eliminates TTX-030
To see what effects TTX-030 combination therapy has on the body
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL